SG11202102471XA - Use of a cathepsin s inhibitor against the formation of anti-drug antibodies - Google Patents

Use of a cathepsin s inhibitor against the formation of anti-drug antibodies

Info

Publication number
SG11202102471XA
SG11202102471XA SG11202102471XA SG11202102471XA SG11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA
Authority
SG
Singapore
Prior art keywords
cathepsin
formation
drug antibodies
inhibitor against
inhibitor
Prior art date
Application number
SG11202102471XA
Other languages
English (en)
Inventor
Christian Klein
Fabrice Alain André Kolb
Young Marianne Manchester
Syed Sohail Ahmed
De Almeida Bessa Juliana Mattos
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202102471XA publication Critical patent/SG11202102471XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202102471XA 2018-09-18 2019-09-18 Use of a cathepsin s inhibitor against the formation of anti-drug antibodies SG11202102471XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18195251 2018-09-18
PCT/EP2019/074918 WO2020058297A1 (fr) 2018-09-18 2019-09-18 Utilisation d'un inhibiteur de la cathepsine s contre la formation d'anticorps anti-médicament

Publications (1)

Publication Number Publication Date
SG11202102471XA true SG11202102471XA (en) 2021-04-29

Family

ID=63787710

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102471XA SG11202102471XA (en) 2018-09-18 2019-09-18 Use of a cathepsin s inhibitor against the formation of anti-drug antibodies

Country Status (15)

Country Link
US (1) US20210315863A1 (fr)
EP (1) EP3852880A1 (fr)
JP (1) JP7438198B2 (fr)
KR (1) KR20210061344A (fr)
CN (1) CN112839716A (fr)
AR (1) AR114732A1 (fr)
AU (1) AU2019344567A1 (fr)
CA (1) CA3112032A1 (fr)
CR (1) CR20210143A (fr)
IL (1) IL281444A (fr)
MA (1) MA53635A (fr)
MX (1) MX2021003127A (fr)
SG (1) SG11202102471XA (fr)
TW (1) TW202023542A (fr)
WO (1) WO2020058297A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7196094B2 (ja) * 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
US20210332122A1 (en) * 2020-04-17 2021-10-28 Cedars-Sinai Medical Center Dysregulation of covid-19 receptor associated with ibd
WO2023245008A1 (fr) * 2022-06-13 2023-12-21 Genentech, Inc. Procédés de retardement ou de prévention de l'apparition de la maladie d'alzheimer à l'aide de crenezumab

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1629012B1 (fr) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Compositions pharmaceutiques comprenant des constructions d'anticorps anti-cd3, anti-cd19 bispecifiques pour le traitement de troubles associes aux lymphocytes b
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
CA2648947A1 (fr) 2006-04-10 2007-11-15 Fusion Antibodies Limited Therapie ciblant la cathepsine s
NZ580755A (en) 2007-04-03 2012-05-25 Micromet Ag Cross-species-specific cd3-epsilon binding domain
NZ595073A (en) * 2009-04-20 2012-11-30 Hoffmann La Roche Proline derivatives as cathepsin inhibitors
SI2673294T1 (sl) 2011-02-10 2016-08-31 Roche Glycart Ag Mutirani polipeptidi interlevkina-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN104114549A (zh) * 2012-02-17 2014-10-22 霍夫曼-拉罗奇有限公司 新型吡咯烷衍生物
EP3359568B1 (fr) 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Anticorps bispécifiques avec tétravalence pour un récepteur de tnf costimulant
BR112018003984A2 (pt) * 2015-12-09 2018-09-25 Hoffmann La Roche anticorpos
MX2018009638A (es) 2016-02-26 2018-09-11 Hoffmann La Roche Derivados novedosos de pirrolidina.
AU2018359506A1 (en) 2017-11-01 2020-04-23 F. Hoffmann-La Roche Ag Combination therapy with targeted OX40 agonists

Also Published As

Publication number Publication date
CR20210143A (es) 2021-04-21
JP7438198B2 (ja) 2024-02-26
IL281444A (en) 2021-04-29
US20210315863A1 (en) 2021-10-14
MX2021003127A (es) 2021-05-14
MA53635A (fr) 2022-04-13
AU2019344567A1 (en) 2021-03-25
AR114732A1 (es) 2020-10-07
EP3852880A1 (fr) 2021-07-28
TW202023542A (zh) 2020-07-01
CN112839716A (zh) 2021-05-25
JP2022501356A (ja) 2022-01-06
KR20210061344A (ko) 2021-05-27
CA3112032A1 (fr) 2020-03-26
WO2020058297A1 (fr) 2020-03-26

Similar Documents

Publication Publication Date Title
IL281444A (en) Use of cathepsin S inhibitor against the formation of anti-drug antibodies
GB201820331D0 (en) Distributed acoustic sensing autocalibration
GB201904329D0 (en) Fluid connection deivce
EP3893891A4 (fr) Formes solides d'un inhibiteur de cd73 et leur utilisation
CA187829S (en) Hand shower
GB2600344B (en) Sonic through tubing cement evaluation
CA190426S (en) Faucet body
GB201819126D0 (en) Inhibitor compounds
CA185189S (en) Faucet body
CA194355S (en) Faucet body
ZA201904876B (en) Combinations of a h3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof
GB201614053D0 (en) Determining the condition of a wound
GB201901640D0 (en) Antibodies against hepcr
EP3884942A4 (fr) Utilisation de bulleyaconitine a
EP3749367A4 (fr) Utilisation d'un anticorps monoclonal ghr-106 en tant qu'antagoniste de gnrh
GB2571799B (en) A navigational device
GB201806573D0 (en) A navigating device
IL256730A (en) A valve that includes sensors
IL263932A (en) Element for finishing a connection between plasterboards
IL279000A (en) Treatment with AGI-134 together with a checkpoint inhibitor for the treatment of solid cancerous tumors
GB201918931D0 (en) Shower hose
UA40563S (uk) Труба розтрубна
GB201805272D0 (en) A sound-absorbing raft
CA191646S (en) Hand pipe
GB201819845D0 (en) Hose closure